In this issue:
Factors modifying the associations of single or combination PD-1/PD-L1 inhibitor therapies with survival outcomes in patients with metastatic ccRCC
Evaluation of clear cell, papillary, and chromophobe RCC metastasis sites and association with survival
Pembrolizumab plus axitinib vs sunitinib monotherapy as 1st-line treatment of advanced RCC (KEYNOTE-426)
Obesity diminishes response to PD-1-based immunotherapies in renal cancer
A systematic review and meta-analysis of the significance of BMI on kidney cancer outcomes
Adjuvant sorafenib for RCC at intermediate or high risk of relapse: results from the SORCE trial
Efficacy and safety of nivolumab+ipilimumab vs sunitinib in first-line treatment of patients with advanced sarcomatoid RCC
Outcomes in patients with RCC undergoing inferior vena cava ligation without reconstruction vs thrombectomy
Association of surgical delay and OS in patients with T2 renal masses: implications for critical clinical decision-making during the COVID-19 pandemic
A contemporary analysis of the 30-day morbidity and mortality associated with cytoreductive nephrectomy
Please login below to download this issue (PDF)